Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: A cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1043-1054

  Favaloro, E J ^a   Bonar, R ^b   Chapman, K ^c   Meiring, M ^d   Funk Adcock, D ^e  

^a WESTMEAD HOSPITAL   (Australia)

^b Royal College of Pathologists of Australasia RCPA   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d UNIVERSITY OF THE FREE STATE   (South Africa)

^e Esoterix Inc   (United States)

Author keywords

Diagnosis; High molecular weight sensitivity; Laboratory testing; Von Willebrand disease; Von Willebrand factor

Indexed keywords

COLLAGEN BINDING PROTEIN; HIGH MOLECULAR WEIGHT VON WILLEBRAND FACTOR; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS LABORATORY TEST; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN TISSUE; LABORATORY AUTOMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SENSITIVITY ANALYSIS; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR ACTIVITY ASSAY; VON WILLEBRAND FACTOR COLLAGEN BINDING ASSAY; VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ASSAY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CALIBRATION; CLINICAL LABORATORY TECHNIQUES; COLLAGEN; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MOLECULAR WEIGHT; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RISTOCETIN; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84861659830     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04729.x     Document Type: Article

References (40)

1. Favaloro EJ. von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37: 440-55.
2. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
3. Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011; 22: 553-64.
4. Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
5. Koutts J. A short history of diagnostic tests for von Willebrand disease: in memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988). Semin Thromb Hemost 2006; 32: 445-55.
6. Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009; 123: 862-8.
7. Favaloro EJ, Kershaw G, McLachlan AJ, Lloyd J. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease. Semin Thromb Hemost 2007; 33: 745-58.
8. Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 2010; 36: 82-90.
9. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
10. Goodall AH, Jarvis J, Chand S, Rawlings E, O'Brien DP, McGraw A, Hutton R, Tuddenham EG. An immunoradiometric assay for human factor VIII von Willebrand factor (VIII:VWF) using a monoclonal antibody that defines a functional epitope. Br J Haematol 1985; 59: 565-77.
11. Chand S, McCraw A, Hutton R, Tuddenham EGD, Goodall AH. A two-site, monoclonal antibody based immunoassay for von Willebrand factor - demonstration that VWF function resides in a conformational epitope. Thromb Haemost 1986; 55: 318-24.
12. Murdock PJ, Woodhams BJ, Mathews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
13. Nitu-Whalley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV. Identification of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
14. Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrand disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding activity/assay (VWF:CBA) with monoclonal antibody (MAB) based ELISA VWF-detection systems. Thromb Haemost 2000; 84: 541-7.
15. Favaloro EJ. Discrimination of von Willebrand Disease (VWD) subtypes: direct comparison of commercial ELISA-based options used to detect qualitative von Willebrand factor (VWF) defects. Am J Clin Pathol 2000; 114: 608-18.
16. Ahmad S, Ptashkin B, Digiovanni C, Cines DB, Konkle BA, Cuker A. False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IID) von Willebrand disease. Thromb Haemost 2011; 106: 1224-5.
17. De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17: 353-8.
18. Sucker C, Senft B, Scharf RE, Zotz RB. Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006; 12: 305-10.
19. Rodgers SE, Lloyd JV, Mangos HM, Duncan EM, McRae SJ. Diagnosis and management of adult patients with von Willebrand disease in South Australia. Semin Thromb Hemost 2011; 37: 535-41.
20. Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011; 9: 1993-2002.
21. Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K (on behalf of the RCPA QAP in Haematology). 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of Type 2B VWD. Thromb Haemost 2007; 98: 346-58.
22. Chandler WL, Peerschke EIB, Castellone DD, Meijer P, on behalf of the NASCOLA Proficiency Testing Committee. von Willebrand factor assay proficiency testing. The North American specialized coagulation laboratory association experience. Am J Clin Pathol 2011; 135: 862-9.
23. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, López JA. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011; 121: 593-603.
24. Favaloro EJ, Mohammed A, Coombs R, Mehrabani PA. Filtered plasma as a potential cause of clinical misdiagnosis: inappropriate testing in a haematology laboratory. Br J Biomed Sci 1995; 52: 243-48.
25. Favaloro EJ, Soltani S, McDonald J. Potential laboratory misdiagnosis of haemophilia and von Willebrand disorder due to cold activation of blood samples for testing. Am J Clin Pathol 2004; 122: 686-92.
26. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in haemostasis? Semin Thromb Hemost 2008; 34: 612-34.
27. De Luca M, Facey DA, Favaloro EJ, Hertzberg MS, Whisstock JC, McNally T, Andrews RK, Berndt MC. Structure and function of the von Willebrand factor A1 domain. Analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. Blood 2000; 95: 164-72.
28. Favaloro EJ, Facey D, Henniker A. Use of a novel Platelet Function Analyser (PFA-100™) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62: 165-74.
29. Tan FL, Ginsburg D. What a polyclonal antibody sees in von Willebrand factor. Thromb Res 2008; 121: 519-26.
30. Marques MB, Fritsma GA. von Willebrand disease laboratory diagnosis: the saga continues. Am J Clin Pathol 2011; 135: 818-20.
31. Favaloro EJ. von Willebrand factor assay proficiency testing continued. Am J Clin Pathol 2011; 136: 657-9.
32. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104: 1009-21.
33. Favaloro EJ, Bonar R, Marsden K (on behalf of the RCPA QAP Haemostasis Committee). Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21: 178-85.
34. Hillarp A, Stadler M, Haderer C, Weinberger J, Kessler CM, Romisch J. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010; 8: 2216-23.
35. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010; 8: 2842-4.
36. Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Baker R, Hertzberg M, Street A, Marsden K (on behalf of the RCPA QAP in Haematology). Reducing errors in identification of von Willebrand disease: the experience of the Royal college of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 2006; 32: 505-13.
37. Turner T, Nolasco L, Moake J. Generation and breakdown of soluble ultra-large von Willebrand factor multimers. Semin Thromb Hemost 2012; 38: 38-46.
38. Ganderton T, Wong JW, Schroeder C, Hogg PJ. Lateral self-association of VWF involves the Cys2431-Cys2453 disulfide/dithiol in the C2 domain. Blood 2011; 118: 5312-18.
39. Mori F, Rossi P, Nardini I, Gambelli D, Farina C. Evaluation of von Willebrand factor activity in factor VIII/von Willebrand factor concentrates with the automated von Willebrand factor: activity IL test. Blood Coagul Fibrinolysis 2010; 21: 221-8.
40. Lee CA, Hubbard A, Sabin A, Budde U, Castaman G, Favaloro EJ, Friedman KD, Mazurier C, Srivastava A, Weinstein M, Montgomery RR, Lillicrap D, Federici AB. For the working party on VWF assays in VWD diagnosis ISTH-SSC-SC on VWF. Diagnostic repertoire for laboratory diagnosis of von Willebrand disease: results of a blind study in 32 centres worldwide. A Scientific Standardization Committee Communication. J Thromb Haemost 2011; 9: 220-2.